1 Abstracts Presented for the 2014 Society of Gynecologic Oncology’s 45 th Annual Meeting on Women’s Cancer, March 22-25, 2014, Tampa, FL SCIENTIFIC PLENARY I: INNOVATIVE AND PRACTICE-CHANGING CONCEPTS IN GYNECOLOGIC ONCOLOGY, ABSTRACTS 1-6, Saturday, March 22, 2014, 8:25 a.m. – 9:30 a.m. Ballroom B-C ABSTRACT 1 Spatial analysis of geographic location and adherence to treatment guidelines for advanced-stage ovarian cancer: impact of race and socioeconomic status ABSTRACT 2 A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study ABSTRACT 3 Comparison of the performance of human papillomavirus (HPV) primary screening strategies with cytology- based strategies: results from the ATHENA trial 3-year follow-up phase Lecturette: Wendy Brewster, MD, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC ABSTRACT 4 Bariatric surgery decreases the risk of uterine malignancy ABSTRACT 5 A cost-utility analysis of Gynecologic Oncology Group protocol 218: the importance of incorporating prospectively collected quality-of-life scores in health outcomes research Lecturette: The TCGA Concept Kathleen Moore, MD ABSTRACT 6 Evaluation of incidence and prognostic significance of newly identified hotspot mutations in DNA polymerase epsilon (POLE) in endometrial cancer: contextualizing findings from The Cancer Genome Atlas Research Network Questions and Floor Discussion
34
Embed
Abstracts Presented for the 2014 Society of Gynecologic ... · 45th Annual Meeting on Women’s Cancer, March 22-25, 2014, ... associated with human cervical cancer ... CANCER: INNOVATIONS
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Abstracts Presented for the 2014 Society of Gynecologic Oncology’s 45th Annual Meeting on Women’s Cancer, March 22-25, 2014, Tampa, FL
SCIENTIFIC PLENARY I: INNOVATIVE AND PRACTICE-CHANGING CONCEPTS IN GYNECOLOGIC ONCOLOGY, ABSTRACTS 1-6, Saturday, March 22, 2014, 8:25 a.m. – 9:30 a.m. Ballroom B-C
ABSTRACT 1 Spatial analysis of geographic location and adherence to treatment guidelines for advanced-stage ovarian cancer: impact of race and socioeconomic status
ABSTRACT 2
A randomized phase III trial of gemcitabine + docetaxel + bevacizumab or placebo as first-line treatment for
metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study
ABSTRACT 3
Comparison of the performance of human papillomavirus (HPV) primary screening strategies with cytology-
based strategies: results from the ATHENA trial 3-year follow-up phase
Lecturette:
Wendy Brewster, MD, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
ABSTRACT 4
Bariatric surgery decreases the risk of uterine malignancy
ABSTRACT 5
A cost-utility analysis of Gynecologic Oncology Group protocol 218: the importance of incorporating
prospectively collected quality-of-life scores in health outcomes research
Lecturette: The TCGA Concept
Kathleen Moore, MD
ABSTRACT 6
Evaluation of incidence and prognostic significance of newly identified hotspot mutations in DNA polymerase
epsilon (POLE) in endometrial cancer: contextualizing findings from The Cancer Genome Atlas Research
Network
Questions and Floor Discussion
2
FOCUSED PLENARY I: TRANSLATIONAL RESEARCH, CONCEPT TO CLINIC, ABSTRACTS 7-11,
Saturday, March 22, 2014, 11:00 a.m. – 12:00 p.m. Ballroom A
ABSTRACT 7
Long noncoding RNA HOTAIR is associated with human cervical cancer progression
ABSTRACT 8 Biological effects of metformin in a preoperative window clinical trial for endometrial cancer
ABSTRACT 9 Omentin: a potential tumor suppressor in the microenvironment associated with visceral obesity
ABSTRACT 10 Germline mutations in DNA repair genes in women with ovarian, peritoneal, or Fallopian tube cancer treated on GOG protocols 218 and 262
ABSTRACT 11
Molecular profiling of tumors from stage I versus stage III/IV cancer patients: a prediction signature for
metastasis in Gynecologic Oncology Group 8024
Lecturette:
Jeff Boyd, MD, Fox Chase Cancer Center, Philadelphia, PA
Questions and Floor Discussion
FOCUSED PLENARY II: SEXUAL HEALTH AND THE GERIATRIC POPULATION, ABSTRACTS 12-16,
The sensitivity of sentinel lymph nodes identified with robotic fluorescence imaging for detecting metastatic
endometrial cancer: interim results from the FIRES trial
ABSTRACT 56
Sentinel lymph node mapping for uterine cancer: a practical illustration of injection and mapping techniques
ABSTRACT 57
Isolated sentinel lymph node biopsy with conservative management in women diagnosed with vulvar cancer
ABSTRACT 58
Abdominal radical trachelectomy (ART): what’s the role in fertility-sparing surgery for cervical malignancies?
SCIENTIFIC PLENARY IV: PREDICTORS OF OUTCOMES IN GYNECOLOGIC CANCERS: WHAT CAN
WE LEARN, ABSTRACTS 59-64, Sunday, March 23, 2014, 11:00 a.m. – 12:45 p.m. Ballroom B-C
ABSTRACT 59
A prospective trial evaluating the ability of preoperative CT scan and serum CA-125 to predict suboptimal
cytoreduction at primary debulking surgery for advanced ovarian, Fallopian tube, and peritoneal cancer
ABSTRACT 60
Predictive model for preoperative determination of microscopic residual disease at the time of primary
cytoreduction in patients with advanced-stage epithelial ovarian cancer: a Gynecologic Oncology Group
(GOG) 182 analysis
ABSTRACT 61
Molecular predictors of residual disease in patients with ovarian cancer
Lecturette:
Beth Karlan, MD, Cedars-Sinai Medical Center, Los Angeles, CA
7
ABSTRACT 62
Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial
ovarian, Fallopian tube, and peritoneal cancers: A GOG study
ABSTRACT 63
Frailty index predicts severe complications in gynecologic oncology patients
ABSTRACT 64
Preoperative quality of life in gynecologic oncology patients: a new predictor of operative risk?
Lecturette:
Vivian von Gruenigen, MD, Northeast Ohio Medical University, Rootstown, OH
Questions and Floor Discussion
FEATURED POSTER III: OVARIAN CANCER: INNOVATIONS AND CONTROVERSIES, ABSTRACTS 65-
69, Sunday, March 23, 2014, 12:45 p.m. – 1:30 p.m. West Hall
ABSTRACT 65
An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with
clear cell carcinoma vs.serous carcinoma treated with platinum therapy: a Gynecologic Oncology Group
(GOG) experience
ABSTRACT 66
Comparative effectiveness of treatments for recurrent ovarian cancer
Discussant: Anil Sood, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
ABSTRACT 67
Short-term morbidity and mortality associated with cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy for recurrent/advanced-stage ovarian cancer
ABSTRACT 68
Primary debulking surgery or neoadjuvant chemotherapy: what is the optimal treatment approach for obese
patients with ovarian/Fallopian tube/primary peritoneal carcinoma?
ABSTRACT 69
Launching personalized surgical therapy for advanced ovarian cancer
Discussant: Laurel Rice, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI
FOCUSED PLENARY IV: INNOVATIONS IN IMMUNOTHERAPY, ABSTRACTS 70-74, Sunday, March 23, 2014, 1:45 p.m. – 3:00 p.m. Ballroom D ABSTRACT 70
Phase I evaluation of therapeutic HPV16 E7 vaccination before resection of HPV16+ CIN2/3
ABSTRACT 71
Phase II trial of paclitaxel, 13-cis retinoic acid, and interferon-alfa-2b in the treatment of advanced stage or
recurrent cervical cancer
8
ABSTRACT 72
Nationwide assessment of human papillomavirus (HPV) genotypes in cancers: implications for prevention
and monitoring impact of current and future (9-valent) HPV vaccines in the United States
Lecturette:
Warner Huh, MD, University of Alabama at Birmingham, Birmingham, AL
ABSTRACT 73
ombination immunotherapy enhances survival in patients with recurrent ovarian cancer
ABSTRACT 74
A phase I trial of a DNA plasmid-based vaccine targeting insulin-like growth factor binding protein-2 (IGFBP-
2) in patients with advanced ovarian cancer: preliminary safety and immunogenicity
Lecturette:
Monica Brown Jones, MD, MS, FACS, FACOG, Cancer Centers of North Carolina, Raleigh, NC
Questions and Floor Discussion
FOCUSED PLENARY V: OBESITY INDUCED CHALLENGES IN ENDOMETRIAL CANCER, ABSTRACTS
75 – 79, Sunday, March 23, 2014, 1:45 p.m. – 3:00 p.m. Ballroom A
ABSTRACT 75
The economic impact associated with caring for the morbidly obese with endometrial cancer: a nationwide
study of 6,560 women
ABSTRACT 76
Complications and surgical staging of endometrial cancer with respect to obesity: a Gynecologic Oncology
Group LAP2 ancillary data study
Lecturette: Tips and Tricks for Operating on the Super Morbidly Obese
Pamela Stone, MD, University of Arkansas, Little Rock, AR
ABSTRACT 77
The link between obesity and endometrial cancer: a lack of knowledge but an opportunity for intervention
ABSTRACT 78
Novel exercise, weight loss, and dietary approach to your life study (NEWDAY) in overweight endometrial
and breast cancer survivors
ABSTRACT 79
Metformin and the risk of endometrial cancer: a population-based cohort study
Lecturette: Overview of obesity in endometrial cancer and future directions
Angeles Secord, MD, Duke University Medical Center, Durham, NC
Questions and Floor Discussion
9
FEATURED POSTER SESSION IV: CANCER IN ELDERLY AND UNDERSERVED POPULATIONS, ABSTRACTS 80 – 93, Monday, March 24, 2014, 7:00 a.m. – 8:00 a.m. Ballroom A
ABSTRACT 80 Dose delay, but not dose reduction, in chemotherapy administration is associated with decreased survival in elderly women with ovarian cancer
ABSTRACT 81
An American College of Surgeons-National Surgical Quality Improvement Project (ACS-NSQIP) evaluation of
surgical outcomes in the elderly: endometrial cancer patients undergoing hysterectomy
ABSTRACT 82
Gaps in adjuvant treatment in elderly endometrial cancer patients
ABSTRACT 83
Improving quality of care with cervical cancer patient navigation
ABSTRACT 84
Risk factors and impact of refusing recommended therapy in cervical cancer: a National Cancer Data Base
(NCDB) study
Discussant: Trey Leath, MD, University of Alabama at Birmingham, Birmingham, AL
ABSTRACT 85
Preoperative chlorhexidine wipes reduce the risk of surgical-site infections after hysterectomy
ABSTRACT 86
The risk factors for readmission in postoperative gynecologic oncology patients at a single institution
ABSTRACT 87
Surgeons as active leaders in the operating room: potential cost-saving behaviors
ABSTRACT 88
Gynecologic surgical-site infection reduction program (GSRP): a successful quality improvement project in
reducing the incidence of surgical-site infection
ABSTRACT 89
Characteristics of high-volume gynecologic cancer centers – framework toward centers of excellence: a
National Cancer Data Base (NCDB) study
Discussant: Kian Behbakht, MD, University of Colorado, Denver, CO
ABSTRACT 90
The role of adjuvant radiation and chemoradiation in single node-positive vulvar cancer
ABSTRACT 91
Barriers to human papillomavirus (HPV) vaccination: perspectives of parents of vaccine-eligible children
ABSTRACT 92
Human papillomavirus vaccination within a Southern California integrated healthcare system demonstrates
disparities in adherence rates among males and females compared to national reports
ABSTRACT 93
Magnitude of increased lifetime risk of cervical cancer and death from cervical cancer with new screening
recommendations
Discussant: Diljeet Singh, MD, Banner MD Anderson Cancer Center, Gilbert, AZ
10
Questions and Floor Discussion
FEATURED POSTER SESSION V: CLINICAL TRIALS AND DRUG REPURPOSING, ABSTRACTS 94 –
ABSTRACT 136 A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – a Gynecologic Oncology Group study
ABSTRACT 137
Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and
bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive
recurrent ovarian cancer
ABSTRACT 138
Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or
placebo in women with recurrent ovarian cancer
ABSTRACT 139
Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in
combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology
Group study 262
SEMINAL ABSTRACT: 1
Presentation of seminal clinical data from Gynecologic Oncology Group study 262
(Presented at the European Society of Gynecologic Oncology)
Questions and Panel Discussion
SCIENTIFIC PLENARY VIII: SEMINAL ABSTRACT SESSION: ROLE OF ANTI-ANGIOGENIC AGENTS
Concurrent chemoradiation with paclitaxel in high-risk endometrial cancer patients after surgery: a Korean
Gynecologic Oncology Group study
ABSTRACT 141
Multimodal therapy improves progression-free survival in patients with stage I-III uterine carcinosarcoma: a
multi-institutional study
ABSTRACT 142
A cost-effectiveness analysis of four chemotherapy regimens used in the treatment of platinum-sensitive
recurrent epithelial ovarian carcinoma
ABSTRACT 143
Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical
cancer: a Gynecologic Oncology Group (GOG) study
ABSTRACT 144
High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from
antiangiogenesis therapy: a Gynecologic Oncology Group (GOG) study
ABSTRACT 145
A comparative analysis of the treatment strategies for advanced ovarian cancer
Questions and Floor Discussion
POSTER SESSION A, Saturday, March 22, 2014, Exhibit Hall
Breast Cancer, Cervical Cancer, Chemotherapy, Clinical Practice Issues, Hereditary Cancers and the Role of
Genetics, Ovarian/Fallopian Tube/Primary Peritoneal Cancer, Translational Research/Basic Science and
Uterine/Endometrial Cancer
BREAST CANCER
Poster 146: The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels
are associated with triple-negative breast cancer clinical development and clinical outcome
CERVICAL CANCER
Poster 147: Analysis of the effect of adjuvant radiotherapy on outcome and complications after radical
hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors
Poster 148: The impact of multiple high-risk factors on survival outcome of surgically treated early-stage
cervical cancer
Poster 149: Cervical adenocarcinoma in situ with coexisting squamous cell lesions: impact on recurrence
Poster 150: A new suggested pattern-based clinical classification system for endocervical adenocarcinoma
Poster 151: Differentiation between high- and low-grade cervical intraepithelial neoplasia by p16
immunoexpression
Poster 152: Risk factors for cervical intraepithelial neoplasia (CIN) recurrence in patients with positive cone
margins
16
Poster 153: The diagnostic utility of HR-HPV as a predictor of cervical cancer recurrence
Poster 154: Synaptonemal complex protein 3 is a prognostic marker in cervical cancer
Poster 155: MICA/B and ULBP1 natural killer group 2 member D (NKG2D) ligands are independent
predictors of prognosis in cervical cancer
Poster 156: Impact of treatment time on chemoradiotherapy in locally advanced cervical carcinoma
Poster 157: Makorin ring finger protein 1 (MKRN1) as an adjunct marker in liquid-based cervical cytology
Poster 158: High rates of cervical intraepithelial neoplasia (CIN) 3 in young women undergoing immediate
excisional procedure for high-grade squamous intraepithelial lesion (HSIL) cytology
Poster 159: Fertility-sparing surgery after high dose-dense neoadjuvant chemotherapy: critical view of
experiences with 25 patients
Poster 160: Efficacy of adjuvant chemotherapy after radical hysterectomy in FIGO stage IB-IIA cervical
cancer: comparison with adjuvant RT/CCRT using Propensity Scores
Poster 161: Less radical surgery than radical trachelectomy or radical hysterectomy in patients with stage I
cervical cancer
Poster 162: A study of safe criteria for radical trachelectomy in cervical cancer patients to prevent
recurrence and catastrophic consequences: a multicenter study
Poster 163: Less radical surgery for early-stage cervical cancer: can cold knife cone specimens help
identify those at low risk for parametrial involvement?
Poster 164: Adenocarcinoma indicates more favorable prognosis with cervix cancer
Poster 165: Diagnosis of adenocarcinoma in situ (AIS): changing trends and the impact of human
papillomavirus (HPV) testing
Poster 166: Prognostic role of maximum standardized uptake value of metastatic pelvic lymph node in
patients with early-stage cervical cancer for the prediction of distant metastasis
CHEMOTHERAPY Poster 167: Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: an institutional experience Poster 168: A dose-dense paclitaxel and carboplatin regimen is highly active in the treatment of recurrent
and advanced endometrial cancer
Poster 169: Oxaliplatin is a safe alternative therapeutic option for patients with recurrent gynecologic
cancers following hypersensitivity reaction to carboplatin
Poster 170: Distribution of ovarian cancer recurrence following intravenous (IV) and intraperitoneal (IP)
adjuvant chemotherapy after upfront cytoreductive surgery
Poster 171: A dose a day keeps the cancer away: metronomic albumin-bound paclitaxel and topotecan has
potent antitumor activity in ovarian cancer
Poster 172: Nanoparticle albumin-bound (nab) paclitaxel therapy in patients with primary and recurrent
ovarian, Fallopian tube, and primary peritoneal carcinoma
Poster 173: Serum antibodies recognizing hypoxia-inducible factor 1-alpha and platinum sensitivity in
ovarian cancer
17
Poster 174: Is it equivalent? a comparison of the clinical activity of Lipodox compared to Doxil in the
treatment of recurrent ovarian cancer
CLINICAL PRACTICE ISSUES
Poster 175: Semi-quantitative human papillomavirus virus (HPV) viral load correlates with the presence
and grade of preneoplastic lesions of the uterine cervix in patients with atypical squamous cells of
undetermined significance (ASCUS) cytology
Poster 176: Narrative medicine: using reflective writing workshops to help house staff address the complex
and challenging nature of caring for gynecologic oncology patients
Poster 177: Evaluating an adnexal mass using a multivariate index assay and imaging
Poster 178: Is hysterectomy safe after concurrent radiochemotherapy of cervical cancer?
Poster 179: Determinants of pelvic and para-aortic lymph node metastasis in endometrial cancer and its
role in tailoring lymphadenectomy
Poster 180: Perioperative thromboembolism prophylaxis: how much is enough?
Poster 181: Malignant endometrial polyps in uterine serous carcinoma: does size matter?
Poster 182: Trends in patient care after discontinuation of daily progress checklists aftertransition to
electronic patient documentation: evaluation of prophylactic compliance and surgical outcomes among
gynecologic oncology patients
Poster 183: Preoperative hypoalbuminemia is a risk factor for 30-day morbidity after gynecologic
malignancy surgery
Poster 184: Factors associated with clinical trial screening failures in gynecologic oncology
Poster 185: Prediction model for 30-day morbidity after gynecologic malignancy surgery
Poster 186: Gynecologic oncology fellow perspectives on research and career development symposia: a
Gynecologic Oncology Fellows’ and Allied Health Professionals’ Research Network (GOFRN) survey study
HEREDITARY CANCERS AND THE ROLE OF GENETICS
Poster 187: Assessment of primary care providers’ current clinical practices in determining a woman’s risk
for ovarian cancer
Poster 188: A new Lynch syndrome: what is the role for polymerase D1 mutations in hereditary
endometrial cancer?
Poster 189: Prevalence and clinical predictors of germline PTEN mutation in endometrial cancer patients
with Cowden and Cowden-like syndrome
Poster 190: Germline SDHB/C/D variation and KLLN promoter methylation in endometrial cancer patients
with Cowden and Cowden-like syndrome
Poster 191: PD-0332991, a cyclin-dependent kinase 4/6 inhibitor, is an active agent in uterine cancer cells